Would you want to know?

SELECT-HD (NCT05032196) is an adaptive trial designed to rapidly optimize dose level and frequency based on early indicators of target engagement. The trial update announced today is being driven by the observation of reductions of mutant huntingtin (mHTT) protein in cerebrospinal fluid (CSF) after study participants received either a single 30 or 60 mg dose ... Read more

This is your downloadable copy of the HD News Winter 2022 edition. In this edition you'll be able to read up on the Walk 4 Hope and how to register, HDNA and the map-HD registry and more.

People with Huntington’s disease require high levels of specialised care in order for them to manage daily living tasks. Specialised housing for people with Huntington’s disease in Australia is limited. This is in part due to a lack of funding and in part due to a lack of appropriate facilities. For many people, this means that their only option is to live in residential aged care (RAC). Living in RAC is generally not appropriate given that the environment often has a lack of age-appropriate activities, and social interaction.

The end of the financial year is just around the corner, and we need your help. You can support the valuable work of Huntington’s NSW ACT by kindly making a tax-deductible donation before June 30. Your donations will help our team connect and care for individuals and families affected by Huntington’s Disease across NSW and the ACT.

Please join with the HDNA as we work toward facilitating the best quality of life for every Australian affected by Huntington’s Disease (HD). Now more than ever, research teams and companies across the globe are testing possible treatments for Huntington’s Disease.

The Neurological Alliance Australia (NAA) seeks commitments from parties and candidates for the upcoming Federal Election to address the urgent needs of adults and children living with neurological diseases in Australia.